Article
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.
Journal of clinical laboratory analysis - 1 Jan 2018
Saladini Francesco, Giannini Alessia, Boccuto Adele, Vicenti Ilaria, Zazzi Maurizio
Abstract excerpt
BACKGROUND: Although clinical management of drug resistance is routinely based on genotypic methods, phenotypic assays remain necessary for the characterization of novel HIV-1 inhibitors, particularly against common drug-resistant variants. We describe the development and assessment of the performance of a recombinant virus assay for measuring HIV-1 susceptibility to protease (PR), reverse transcriptase (RT), and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.